KR101607244B1 - 뇌혈관 연축의 예방을 위한 약물 전달 시스템 - Google Patents

뇌혈관 연축의 예방을 위한 약물 전달 시스템 Download PDF

Info

Publication number
KR101607244B1
KR101607244B1 KR1020147036026A KR20147036026A KR101607244B1 KR 101607244 B1 KR101607244 B1 KR 101607244B1 KR 1020147036026 A KR1020147036026 A KR 1020147036026A KR 20147036026 A KR20147036026 A KR 20147036026A KR 101607244 B1 KR101607244 B1 KR 101607244B1
Authority
KR
South Korea
Prior art keywords
calcium channel
vasospasm
cerebral
therapeutic agent
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147036026A
Other languages
English (en)
Korean (ko)
Other versions
KR20150015514A (ko
Inventor
알. 로치 맥도날드
브라이언 로이트너
Original Assignee
알. 로치 맥도날드
브라이언 로이트너
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알. 로치 맥도날드, 브라이언 로이트너 filed Critical 알. 로치 맥도날드
Publication of KR20150015514A publication Critical patent/KR20150015514A/ko
Application granted granted Critical
Publication of KR101607244B1 publication Critical patent/KR101607244B1/ko
Assigned to 에쥐 세라피틱스, 인코포레이티드 reassignment 에쥐 세라피틱스, 인코포레이티드 권리의 전부이전등록 Assignors: 로이트너, 브라이언, 맥도날드, 알., 로치
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147036026A 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템 Expired - Fee Related KR101607244B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94312407P 2007-06-11 2007-06-11
US60/943,124 2007-06-11
US97690207P 2007-10-29 2007-10-29
US60/976,902 2007-10-29
PCT/US2008/066576 WO2008154585A1 (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107000554A Division KR101554250B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Publications (2)

Publication Number Publication Date
KR20150015514A KR20150015514A (ko) 2015-02-10
KR101607244B1 true KR101607244B1 (ko) 2016-03-30

Family

ID=40096090

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147036026A Expired - Fee Related KR101607244B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템
KR1020107000554A Expired - Fee Related KR101554250B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템
KR1020157012919A Expired - Fee Related KR101554258B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020107000554A Expired - Fee Related KR101554250B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템
KR1020157012919A Expired - Fee Related KR101554258B1 (ko) 2007-06-11 2008-06-11 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Country Status (10)

Country Link
US (2) US8303974B2 (https=)
EP (1) EP2164497B1 (https=)
JP (1) JP5576790B2 (https=)
KR (3) KR101607244B1 (https=)
CN (3) CN101873858B (https=)
AU (1) AU2008261668C1 (https=)
CA (1) CA2690600C (https=)
IL (1) IL202647A (https=)
NZ (2) NZ581836A (https=)
WO (1) WO2008154585A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303974B2 (en) * 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US8252302B2 (en) * 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
EP2308478A1 (en) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
EP2627173B2 (en) 2010-10-12 2018-07-04 Chiesi Farmaceutici S.p.A. Clevidipine emulsion formulations containing antimicrobial agents
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
EP2672983B1 (en) * 2011-02-11 2017-04-19 Edge Therapeutics, Inc. Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
HK1198933A1 (en) * 2011-04-05 2015-06-19 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
CN102416013A (zh) * 2011-12-30 2012-04-18 湖南九典制药有限公司 西尼地平的新用途
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
WO2014165023A1 (en) 2013-03-12 2014-10-09 Carnegie Mellon University Coated vaso-occclusive device for treatment of aneurysms
CN103211812A (zh) * 2013-04-02 2013-07-24 苏州大学附属第一医院 Skf96365在治疗蛛网膜下腔出血后发生的脑血管痉挛的应用
US10403395B2 (en) * 2013-10-14 2019-09-03 SecondOpinionExpert, Inc. Method and apparatus for generating objective medical second opinion
CA2975447C (en) * 2015-01-30 2021-02-23 The Regents Of The University Of California Spinal subpial gene delivery system
KR20180021741A (ko) * 2015-05-29 2018-03-05 에쥐 세라피틱스, 인코포레이티드 시각 손실을 감소시키기 위한 조성물 및 방법
US10695400B2 (en) * 2015-08-03 2020-06-30 Enb Therapeutics, Inc. Compositions and methods for treating cancers associated with ETBR activation
AU2018300080B2 (en) 2017-07-11 2024-09-19 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
US20200163947A1 (en) * 2018-11-02 2020-05-28 Nortic Holdings Inc. Methods of treatment using nimodipine parenteral formulations
US11103142B2 (en) 2019-04-02 2021-08-31 Tencent America LLC System and method for predicting vertebral artery dissection
US20200315547A1 (en) * 2019-04-02 2020-10-08 Tencent America LLC Vertebral artery dissection risk evaluation method, computer device, and storage medium
JP7716076B2 (ja) * 2021-02-04 2025-07-31 学校法人産業医科大学 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
WO1995018972A1 (en) 1994-01-05 1995-07-13 Arqule, Inc. Systematic modular production of aminimide- and oxazolone-based molecules having selected properties
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
JP2909418B2 (ja) * 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US6123956A (en) 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6284283B1 (en) * 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) * 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
CN1480128A (zh) * 2003-08-06 2004-03-10 北京扬新科技有限公司 一种透明、隐形的外用药物制剂
BRPI0414907A (pt) * 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
WO2006084005A2 (en) * 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
US8303974B2 (en) * 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity

Also Published As

Publication number Publication date
CN101873858A (zh) 2010-10-27
CA2690600A1 (en) 2008-12-18
NZ581836A (en) 2012-07-27
JP5576790B2 (ja) 2014-08-20
EP2164497A4 (en) 2013-05-29
KR20100055385A (ko) 2010-05-26
KR101554258B1 (ko) 2015-09-18
US20080305147A1 (en) 2008-12-11
JP2010529205A (ja) 2010-08-26
KR101554250B1 (ko) 2015-09-18
US20130022660A1 (en) 2013-01-24
AU2008261668A1 (en) 2008-12-18
CN105055300A (zh) 2015-11-18
US8303974B2 (en) 2012-11-06
EP2164497A1 (en) 2010-03-24
WO2008154585A1 (en) 2008-12-18
KR20150061031A (ko) 2015-06-03
CA2690600C (en) 2016-10-11
AU2008261668B2 (en) 2013-08-29
CN101873858B (zh) 2016-05-25
NZ599430A (en) 2014-03-28
CN105963242A (zh) 2016-09-28
IL202647A0 (en) 2010-06-30
AU2008261668C1 (en) 2014-01-16
EP2164497B1 (en) 2018-08-15
KR20150015514A (ko) 2015-02-10
IL202647A (en) 2015-02-26

Similar Documents

Publication Publication Date Title
KR101607244B1 (ko) 뇌혈관 연축의 예방을 위한 약물 전달 시스템
RU2606169C2 (ru) Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
JP6146814B2 (ja) クモ膜下出血のヒトの予後を改善する組成物及び方法
AU2016201681B2 (en) A drug delivery system for the prevention of cerebral vasospasm
CA2826890A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
AU2013203192B2 (en) A drug delivery system for the prevention of cerebral vasospasm
HK1229243A1 (en) A drug delivery system for the prevention of cerebral vasospasm
HK1230079A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
NZ613970B2 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20190324

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190324

St.27 status event code: N-4-6-H10-H13-oth-PC1903